natgillin/translations-raw huggingface dataset:
wherein the package contains tobacco-related articles, wherein the tobacco-related articles are selected from the group consisting of cigarettes, cigarillos, cigars, tobacco-containing rods, smokeless tobacco, simulated smoking devices, inhalors without combustion of tobacco, and aroma reservoirs. 
90; 100) sadržava proizvode koji su vezani uz duhan, pri čemu su proizvodi koji su vezani uz duhan odabrani iz sljedećih skupina: cigarete, cigarilosi, cigare, štapići koji sadržavaju duhan, duhan bez dima, naprave koje simuliraju pušenje, naprave za inhaliranje bez izgaranja duhana, rezervoari s aromom.
The composition for use according to any one of the preceding claims, wherein the said polypeptides comprise at least 90% of the proteins present in the preparation. 
Sastav za uporabu u skladu sa zahtjevom 4, naznačen time, što je svaka sekvenca polinukleotida sposobna iskazati različit polipeptid prisutan u istim ili različitim polinukleotid vektorima.
In all above mentioned embodiments, the medication delivery device can comprise a locking means which is non-rotatable with respect to the housing and which is engageable with the reset element, thereby locking the reset element for preventing rotation of the reset element with respect to the housing in the operational state. 
Naprava za unos lijeka (1) u skladu s patentnim zahtjevom 16, naznačena time što element za resetiranje (11) je matica, koja je navojem spojena s klipom (17) i koja se spaja s bravom u radnom položaju.
Cosmetic composition according to claim 1 or 2, characterized in that the compound of general formula (I) is in the form of a hydrate or of a solvate. 
Spoj prema zahtjevu 1 ili 2, naznačen time da je u obliku hidrata ili solvata.
In some embodiments, compounds of the present invention are of Formula (It) wherein X is NH. 
U nekim oblicima, spojevi prikazanog izuma su Formule (It) gdje X je NH.
a processor operable to obtain, from a received bitstream, information about a maximum size of a coding unit, information about a prediction unit in the coding unit and information about a transformation unit for transformation of the coding unit; and 
Postupak dekodiranja slike, te postupak sadrži: dobivanje kvantificiranih koeficijenata transformacije za transformacijsku jedinicu u jedinici za kodiranje provođenjem entropijskog dekodiranja na kodiranom toku bitova na temelju jedinice kodiranja;
The compound according to claim 1, having the formula II: 
Spoj u skladu s patentnim zahtjevom 1, s formulom II:
In a preferred embodiment the invention further relates to a marker vaccine for prophylactic treatment of classical swine fever comprising modified live attenuated classical swine fever virus, characterised in that the viral amino acid sequence of the TAV-epitope of the E2 protein comprises a different sequence from that of a wild-type classical swine fever virus, whereby the viral amino acid sequence exhibits at least one of the following substitutions: 
PATENTNI ZAHTJEVI 1. - Marker cjepivo za zaštitno liječenje klasične svinjske groznice sadrži modificirani živi oslabljeni virus svinjske groznice, naznačeno time što virusni aminokiselinski slijed TA V-epitopa proteina E2 obuhvaća slijed različit od divljeg tipa virusa klasične svinjske groznice, tako da aminokiselinski slijed pokazuje najmanje jednu od sljedećih supstitucija u odnosu na C-soj,,Riems" virusa:
is selected from the group consisting of CH2, CR9R10 and a cycle of the formula C(CH2)n, where n = 2-5; 
Tvar iz bilo kojeg od patentnih zahtjeva 1-5, ili njena farmaceutski prihvatljiva sol, pri čemu je Bs odabran iz grupe koja se sastoji od HR P20171021 T1
heating Mixture B to 80°C-120°C to obtain and optionally adding an appropriate acid to the product obtained in step c) to obtain the corresponding salt. 
HR P20190769 T1 i d) izbornog dodavanja odgovarajuće kiseline produktu dobivenom u koraku c) kako bi se dobilo odgovarajuću sol.
The method according to claim 11, wherein said rinsing cartridge is provided with a switch for selectively supplying rinsing fluid from said rinsing cartridge to one tapping line of the said plurality of beverage dispensing systems. 
Metoda u skladu sa patentnim zahtjevom 10, gdje je navedeni spremnik za pranje (20,118,132) osiguran sa prekidačem za selektivno osiguravanje fluida za pranje iz navedenog spremnika za pranje (20,118,132) do jedne linije za točenje (68) od navedenog velikog broja sistema za dispenziranje napitaka.
The antibody of claim 3, wherein the antibody comprises a heavy chain comprising a heavy chain variable region consisting of amino acid sequence SEQ ID NO: 16 and a heavy chain constant region which is a human gamma-1 heavy chain constant region, and a light chain comprising a light chain variable region consisting of amino acid sequence SEQ ID NO: 20 and a light chain constant region which is a human kappa light chain constant region. 
Antitijelo prema zahtjevu 1, pri čemu antitijelo obuhvaća teški lanac koji obuhvaća varijabilno područje teškog lanca koji se sastoji iz sekvence aminokiselina koja je prikazana u SEQ ID NO: 16 i konstantno područje teškog lanca koji je konstantno područje humanog gama-1 teškog lanca, i laki lanac koji obuhvaća varijabilno područje lakog lanca koji se sastoji iz sekvenci aminokiselina koje su prikazane u SEQ ID NO: 20 1 konstantnog područja lakog lanca koji je konstantno područje humanog kapa lakog lanca.
Recombinant proteins can be produced also by transgenic animals and secreted into the milk. 
Rekombinantni proteini mogu se također proizvesti u transgenim životinjama kojc ih izlučuju u mlijeko.
said thiazolidinedione is rosiglitazone or pioglitazone, or combination thereof; 
(ii) navedeni tiazolidindion je rosiglitazon ili pioglitazon, ili njihova kombinacija;
shaping (1040) the second mixture into plates of desired thickness; 
- < oblikovanje (1040) druge mješavine u ploče;
A method of producing a colloidal suspension in a solvent according to embodiment 16, wherein the rotational speed of said milling beads is smaller than 15 m/s such as smaller than 10 m/s, and preferably in the range 5-10 m/s, wherein the rotational speed of the beads preferably is provided by an agitator, preferably rotated with a circumferential speed of the agitator smaller than 15 m/s such as smaller than 10 m/s, and preferably in the range 8-10 m/s. 
Postupak za proizvodnju koloidne suspenzije u otapalu prema zahtjevu 10, naznačen time da je rotacijska brzina navedenih zrnaca za mljevenje (9) manja od 15 m/s na primjer manja od 10 m/s, te je poželjno u rasponu od 5-10 m/s, pri čemu se rotacijska brzina zrnaca za mljevenje (9) poželjno postiže pomoću miješalice, koja poželjno rotira obodnom brzinom miješalice koja je manja od 15 m/s na primjer manja od 10 m/s, te je poželjno u rasponu od 8-10 m/s.
The method of one of the preceding claims, wherein lightweight, heat insulating floor elements are placed and interconnected, and supported if necessary, and thereafter structural fill-material, such as concrete, is poured onto the floor elements to form a floor. 
Postupak gradnje prema jednom od prethodnih zahtjeva, naznačen time da su lagani, toplinski izolirajući podni elementi (18) postavljeni 1 međusobno povezani, i ako je potrebno poduprti, 1 nakon toga je građevni materijal za ispunu kao što je beton, naliven na podne elemente kako bi tvorio pod.
The pharmaceutical composition of any one of claims 12-14, further comprising a cytokine selected from the group consisting of IL-2, IL-3, IL-6, IL-11, IL-12, IL7, IL15, IL21, granulocyte macrophage colony stimulating factor, alpha, beta or gamma interferon and erythropoietin. 
Farmaceutski pripravak namijenjen upotrebi u liječenju neoplazije prema zahtjevu 20, te navedeni pripravak nadalje sadrži citokin odabran 1z skupine koju čine IL-2, IL -3, IL -6, IL -11, IL-12, IL-7, IL -15, IL-21, faktor stimulacije kolonija granulocita i makrofaga, alfa, beta ili gama interferon i eritropoetin.
A pharmaceutical composition comprising one or more compounds of formula I as claimed in any one of claims 1 to 13 or a pharmacologically tolerable salt thereof, together with customary pharmaceutical excipients and/or vehicles. 
Farmaceutski pripravak, naznačen time što sadrži jedan ili više spojeva formule I u skladu s bilo kojim od patentnih zahtjeva 1 do 13, ili njegovu farmakološki prihvatljivu sol, zajedno s uobičajenim farmaceutskim pomoćnim tvarima i/ili vehikulumima.
Ra, Rb, Rc, and Rd are independently selected from the group consisting of H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, heterocyclic, aryl, substituted aryl, acyl, substituted acyl, SO2-alkyl, amino, substituted amino, and NO; or Ra and Rb together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, azetidino, morpholino, or thiomorpholino ring; or Rb and Rc together with the nitrogen to which they are attached form a pyrrolidino, piperidino, piperazino, azetidino, morpholino, or thiomorpholino ring; and 
Ra, Rb, RC,i Rd biraju se neovisno odabirom iz skupine koja se sastoji od H, alkil, supstituiranog alkila, alkenila, supstituiranog alkenil, alkinila, supstituiranog alkinila, cikloalkila, heterocikla, arila, supstituiranog arila, acila, supstituiranog acila, SO2 alkila, amino, supstituiranog amino i NO;
said process comprising the steps of: cyclizing Compound 2 in a first solvent at an elevated temperature wherein R5 and R6 are each independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, alkylaryl, arylalkyl, heterocyclic and heteroaryl groups, or R5 and R6, together with the nitrogen to which they are attached, form a 3- to 6-membered heterocyclic compound containing 1-4 heteroatoms, to produce a first mixture of exo isomers 
(a) ciklizacije Spoja 2 u prvom otapalu, na povišenoj temperaturi gdje svakog od Rs i Rs se neovisno bira iz skupine koju čine H, alkilne, alkenilne, alkinilne, alkoksi, cikloalkilne, arilne, alkilarilne, arilalkilne, heterocikličke i heteroarilne skupine, ili Rs i R4, zajedno s dušikom na kojeg su vezani, tvore 3- do 6-eročlani heterociklički spoj s 1-4 heteroatoma, kako bi se dobilo prvu smjesu exo-izomera gdje navedeni izomeri imaju zrans-[5,6]-vezu u prstenu; i endo-izomera:
The immunoconjugate of any one of claims 1 to 9, wherein said mutant human interleukin-2 (IL-2) polypeptide comprises the polypeptide sequence of SEQ ID NO: 3. 
Imunokonjugat iz bilo kojeg od patentnih zahtjeva 1 do 9, naznačen time, da navedeni mutirani ljudski interleukin-2 (IL-2) polipeptid obuhvaća polipeptidnu sekvencu od SEQ ID NO: 3.
The assembly according to claim 1, wherein said elongated flexible body is at least 45,72 cm (18 inches) long. 
Sklop u skladu s patentnim zahtjevom 1, naznačen time što je navedeno izduženo savitljivo tijelo dugačko najmanje 45,72 cm (18 inča).
A compound of formula (I) or a physiologically acceptable solvate thereof for use in the treatment of patients according to claim 5, wherein the inflammatory and/or allergic condition is conjunctivitis. 
Spoj formule (1), ili njegov fiziološki prihvatljiv solvat, namijenjen upotrebi u liječenju pacijenata u skladu s patentnim zahtjevom 5, naznačen time što upalno i/ili alergijsko stanje je konjunktivitis.
Production of hot water and steam. 
Proizvodnju vruće vode i vodene pare.
Transfer apparatus according to clause 9, wherein the form of the triangle-like carrier body corresponds to the triangle formed by the engage members. 
Prijenosni uređaj prema zahtjevu 9., naznačen time da oblik trokuta tijela (20) nosača odgovara trokutu kojeg čine zahvatni članovi (14, 15, 16).
Step 10—First Stage of the Deprotection: 
Broj objave europskog patenta:
Number of washing step was increased: from 3 to 4 and from 4 to 5 for the last one. 
- > Broj koraka ispiranja je povećan: od 3 na 4 i od 4 na 5 za zadnji korak.
Further aspects, advantages and objects of the present invention will now become evident for the man skilled in the art when reading the following detailed explanation of an embodiment taken in conjunction with the figures of the enclosed drawing. 
Slijedeći aspekti, prednosti 1 ciljevi prema ovom izumu biti će sada očigledni stručnjaku kada čita sljedeće detaljno objašnjenje izvedbe, dano u sprezi sa slikama na uključenom crtežu.
115-116° C. After recrystallisation from tetrahydrofuran, 17.5 g white crystals of 1 were obtained having imp. 
115 - 116C. Nakon rekristalizacije iz tetrahidrofurana, dobiva se 17,5 g bijelih kristala spoja 1 st. t.
The antibody active agent conjugate of claim 1, wherein the active agent is a drug, a toxin, an affinity ligand, a detection probe, an immunomodulatory compound, an anti-cancer agent, an anti-viral agent, an anti-bacterial agent, an anti-fungal agent, or an anti-parasitic agent. 
Konjugat aktivnog sredstva antitijela u skladu s patentnim zahtjevom 1, naznačen time, da je aktivno sredstvo lijek, toksin, afinitetni ligand, detekcijska sonda, imunomodulatorni spoj, sredstvo protiv raka, anti-virusno sredstvo, antibakterijsko sredstvo, anti-gljivično sredstvo ili anti-parazitsko sredstvo.
In particular, aspirating air from the chamber 27 of the guide 6, the force of the spring 30 is overcome and the cursor 7 can thus move within the guide, dragging the rod-like element 8 with it, thus approaching the third suction cup 5 to the second external lateral wall of the container. 
Naročito se kod isisavanja zraka iz komore 27 vodilice 6 nadvladava sila opruge 30 i klizač 7 se na taj način može pomicati unutar vodilice, povlačeći sa sobom element 8 koji ima oblik šipke i time može približiti treću usisnu čašicu 5 na drugu vanjsku bočnu stijenku spremnika.
a CO2 converter for converting CO2 into CO, the CO2 converter comprising at least one further process chamber having at least one inlet for CO2 adapted to introduce CO2 from an external CO2 source into the CO2 converter, at least one inlet for carbon and hydrogen, and at least one outlet, wherein the inlet for carbon and hydrogen is directly connected to the at least one outlet of the hydrocarbon converter. 
pretvornik ugljikovodika za razgradnju tekućine koja sadrži ugljikovodik na ugljik i vodik, pri čemu pretvornik ugljikovodika sadrži najmanje jednu procesnu komoru koja ima najmanje jedan ulaz za tekućinu koja sadrži ugljikovodik i najmanje jedan izlaz za ugljik i/ili vodik i najmanje jednu jedinicu za uvođenje energije u procesnu komoru, energija se sastoji barem djelomično od topline;
(Substituent group A is same meaning as that of item 1′). 
(Supstituentska skupina A ima isto značenje kao što je navedeno u zahtjevu 1).
In contrast to HI chromatography, adsorption of antibodies from cell culture supernatants on HCIC resin is accomplished without the need of any pH or ionic strength adjustment. 
Nasuprot kromatografiji HI, adsorpcija protutijela iz supernatanata staničnih kultura se na smolu HCIC postiže bez potrebe za podešavanjem pH ili ionske jakosti.
A pharmaceutical composition comprising one or more compounds according to any one of claims 1-13 and a pharmaceutically acceptable carrier or diluent. 
= Farmaceutska kompozicija koja sadrži jedan ili više spojeva ili stereoizomer, tautomer, farmaceutski-prihvatljiva sol, ili solvat tog spoja, u skladu sa patentnim zahtjevom 1 1li 2, i farmaceutski prihvatljiv nosač ili razblaživač.
The pharmaceutically acceptable transdermal composition of claim 10, further comprising a basic amino acid selected from arginine, lysine and histidine. 
Farmaceutski prihvatljiv transdermalni sastav iz zahtjeva 10, naznačeno time da je aktivni sastojak entakapon ili farmaceutski prihvatljiva sol istog.
A formulation comprising 
Formulacija koja sadrži
BACKGROUND OF THE INVENTION Corticosteroids and antimuscarinic agents, in particular antagonists of M3 muscarinic receptors, are two classes of drugs useful in the treatment of respiratory disorders, such as asthma or Chronic Obstructive Pulmonary Diseases (COPD). 
B-adrenergički agonisti, osobito B2-adrenergički agonisti i antimuskarinski lijekovi, osobito antagonisti M3 muskarinskih receptora, predstavljaju dva razreda bronhodilatacijskih lijekova korisnih u liječenju respiratornih poremećaja, poput astme ili kronične opstruktivne plućne bolesti (KOPD).
mg povidone mg colloidal SiO2 extragranular components: 
pri čemu se granulacija kombinira s ekstragranularnim komponentama:
A process according to claim 12, wherein said esterase enzyme is an isolated polypeptide with esterase activity comprising an amino acid sequence shown in SEQ ID No. 
Postupak prema zahtjevu 12, naznačen time da navedeni enzim esteraze je izolirani polipeptid s aktivnošću esteraze koji sadrži sekvencu amino kiseline prikazanu u SEQ ID No.
The cake was suction-dried at room temperature. 
Masa je osušena na sobnoj temperaturi.
the anti-cancer agent is a member of the group consisting of anti-cancer agents that exhibits poor selectivity/specificity for cancer cells; anti-cancer agents that exhibit poor uptake by cancer cells; anti-cancer agents that exhibit poor retention in cancer cells; anti-cancer agents that exhibit poor water solubility; anti-cancer agents that undergo premature inactivation in cancer cells; anti-cancer agents that undergo impaired activation in cancer cells; anti-cancer agents that undergo extensive cellular degradation; and anti-cancer agents associated with drug resistance. 
antikancerogeno sredstvo član grupe koja se sastoji od antikancerogenih sredstava koja iskazuju slabu selektivnost/specifičnost prema stanicama karcinoma; antikancerogenih sredstava koja stanice karcinoma slabo preuzimaju; antikancerogenih sredstava koja stanice karcinoma slabo zadržavaju; antikancerogenih sredstava koja iskazuju slabu topivost u vodi; antikancerogenih sredstava koja podliježu preuranjenoj inaktivaciji u stanicama karcinoma; antikancerogenih sredstava koja podliježu oslabljenoj aktivaciji u stanicama karcinoma; antikancerogenih sredstava koja podliježu velikoj razgradnji u stanici; i antikancerogenih sredstava povezanih s otpornošću na lijekove.
about 50-90 mg/ml of the sugar, optionally wherein the sugar is selected from the group consisting of mannitol, sorbitol, sucrose, and trehalose; and/or 
Formulacija prema bilo kojem od zahtjeva 1-5, naznačena time što je šećer odabran iz skupine koja se sastoji od manitola, sorbitola, saharoze i trehaloze.
R1, R2, and R3 in Formula 4 and Formula 5 are as defined in Formula 3; and 
R!', Ri R* u Formuli 4 i Formuli 5 su definirani kao za Formulu 3; i
A process according to claims 12 wherein the addition of the gadobenate solution to the antisolvent B is performed in a time ranging from 2 to 6 hours. 
Postupak prema zahtjevu 15 naznačen time što se dodavanje otopine gadobenat dimeglumina u protuotapalo B provodi u vremenu od 2 do 6 sati.
The ether layer was removed and the aqueous layer extracted with ether (2 x 200 ml. 
Eterski sloj se odvoji i vodeni sloj se ekstrahira sa eterom (2 x 200 ml.
Method according to claim 1 for the identification, and possibly measurement, of at least one transferrin glycoform, preferably carbohydrate-deficient transferrin, selected from: asialo-, monosialo-, disialo- transferrin. 
Postupak prema zahtjevu 1 naznačen time što je za identifikaciju i eventualno mjerenje najmanje jedne glikoforme transferina, poželjno ugljikohidratno deficijentnog transferina, odabrane od: asijalo-, monosijalo-, disijalotransferina.
A compound of Claim 1 which is a crystalline hydrate characterized by an X-ray powder diffraction pattern using CuKa radiation having a peak at 22.97 ±0.2 degrees 2-theta in combination with one or more peaks at 11.96 ±0.2, 18.81 ±0.2, 20.78 ±0.2 or 21.07 ±0.2 degrees 2-theta at ambient temperature and relative humidity. 
Spoj u skladu s patentnim zahtjevom 1, koji je kristalni hidrat, naznačen time što ima karakteristični uzorak difrakcije rendgenskih zraka na prahu, uz upotrebu zračenja CuKa, sa signalom na 22,97 ± 0,2 °2θ, u kombinaciji s jednim ili više signala na 11,96 ± 0,2, 18,81 ± 0,2, 20,78 60,2 ili 21,07 ± 0,2 °2θ na temperaturi i uz relativnu vlažnost okoliša.
Use of an immunogenic composition comprising VZV gE antigen truncated to remove the carboxy terminal anchor region, wherein the gE truncate is not in the form of a fusion protein, and a TH-1 adjuvant comprising 3D-MPL, QS21 and liposomes comprising cholesterol in the preparation of a medicament for the prevention or amelioration of shingles and/or post herpetic neuralgia (i) in a population of individuals aged 50 or older or (ii) in a population of immunocompromised individuals. 
Upotreba VZV antigena gE u pripravi medikamenta za istodobnu ili uzastopnu primjenu uz živi oslabljeni VZV radi sprječavanja ili smanjivanja težine herpes zostera i/ili postherpetične neuralgije kod osoba koje su u opasnosti od takvih bolesti, naznačena time što je VZV antigen gE antigen gE, skraćen kako bi se uklonilo C-terminalno sidrišno područje, gdje se VZV antigen unosi uz adjuvans koji sadrži 3D-MPL, QS21 i liposome koji sadrže kolesterol.
The emulsion according to claim 1 wherein the oil is at least 0.1 w/v % and no greater than 5 w/v. The emulsion according to claim 1 wherein the hydrophilic surfactant is present in the emulsion in an amount that is at least 0.08 w/v % and is present in the emulsion in an amount that is no greater than 0.8 w/v. 
Emulzija prema zahtjevu 1, 2 i 3, naznačena time, da je hidrofilni tenzid prisutan u emulziji u količini koja je najmanje 0,08% masa/volumen i prisutan je u emulziji u količini koja nije veća od 0,8% masa/volumen, dok je poželjno hidrofilni tenzid prisutan u emulziji u količini koja je najmanje 0,14% masa/volumen i prisutan je u emulziji u količini koja nije veća od 0,44% masa/volumen.
R5a is hydrogen, lower alkyl optionally substituted by substituent group C, carbocyclic group optionally substituted by substituent group C, carbocycle lower alkyl optionally substituted by substituent group C, carbocycleoxy lower alkyl optionally substituted by substituent group C, heterocyclic group optionally substituted by substituent group C, heterocycle lower alkyl optionally substituted by substituent group C, heterocycleoxy lower alkyl optionally substituted by substituent group C, —Y—S—RD1, —C(═O)—C(═O)—RD2, or 
a je vodik, niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, karbociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, karbociklil-niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, karbocikliloksi niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, heterociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, heterocikli-niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, heterocikliloksi niži alkil prema potrebi supstituiran sa supstituentskom skupinom C,
A reference signal generation method used by a radio communication appatatus comprising: 
Metoda generiranja referentnog signala za moguću uporabu u Koordiniranom prijenosu i prijemu Više Točaka, CoMP, metoda sadržeći:
SPE (solid phase extraction) refers to the use of cartridges sold by International Sorbent Technology Ltd. 
SPE (ektrakcija u čvrstoj fazi) odnosi se na upotrebu uložaka nabavljrenih od strane firme International Sorbent Technology Ltd.
As described before, the Advanced Basic Media—Mesenchymal stem cell (ABM-M medium) keeps the same cell characteristics and differentiation potency of mesenchymal stem cells, in comparison to the existing mesenchymal stem cell cultured medium. 
0,73. 2. | Napredni osnovni medij za kulturu mezenhimnih matičnih stanica u skladu s patentnim zahtjevom 1, naznačen time što u navedenom mediju mezenhimne matične stanice pokazuju stanične imunološke karakteristike gdje se
(a') reacting a compound of formula 4: or a salt thereof, with a reducing agent to provide a compound of formula 5: or a salt thereof; and 
"A P č4) ili njegove soli, s redukcijskim sredstvom kako bi se dobio spoj prema formuli 5: ili njegova sol; 1
wherein R1 is as defined for the compound of formula (1); 
gdje je RI kao što je definirano za spoj sa formulom (1).
Oxygen gas was bubbled through the reaction mixture for 15 minutes. 
Kroz reakcijsku smjesu se propušta plinoviti kisik tijekom 15 minuta.